3. Results
thirty-nine
SAID
One hundred and twelve patients were assessed for eligibility, and seventy-seven were included in this study. Thirty-eight patients were randomly allocated to the Favipiravir group and thirty-nine to the placebo group (Eight patients in the treatment group and four in the placebo group did not complete the treatment. In the Favipiravir group, three patients discontinued the treatment because they believed that they did not need any medication. One patient declared that because the pills were not labeled, she could not trust them and decided not to use them. Others said that the number of tablets was so many, and it was hard for them to consume so many tablets. The reasons for discontinuation in the control group were the number of tablets in two patients, an AE in one patient, and not specified in the other one. The follow-up was completed for all patients regardless of their compliance.The demographic characteristics of the patients are shown in The primary outcome happened in four patients (10.5%) in the treatment group and two patients (5.1%) in the control group through the 28 days of follow-up. The chi-square test result shows no difference in the proportion of hospitalization between the two groups (No major AEs were reported during the follow-up. Only one patient in the placebo group complained about abdominal discomfort that improved after discontinuing the intervention.